Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended ...

Amgen (NASDAQ: AMGN) is doing something unusual in 2025. Here's why this $150 billion pharmaceutical powerhouse deserves a ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its ...

Amgen threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent. Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to ...

While Enbrel and Otezla are not heart medicines, Amgen (NASDAQ:AMGN) allegedly threatened to deny rebate payments to PBMs unless they picked Repatha over Praluent. “Amgen prevented Regeneron ...

The jury agreed with Regeneron, opens new tab that Amgen unlawfully bundled Repatha with two of its blockbuster anti-inflammatory drugs to persuade pharmacy benefit managers to buy it instead of ...